Thomas Lung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2384224/publications.pdf

Version: 2024-02-01

		393982	433756
56	1,126	19	31
papers	citations	h-index	g-index
E 7	E 7	57	2622
57	57	57	2633
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Investigating socioeconomic inequalities in BMI growth rates during childhood and adolescence. Obesity Science and Practice, 2022, 8, 101-111.	1.0	4
2	Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study. Circulation, 2022, 145, 1534-1541.	1.6	13
3	Economic evaluation of the e-Health <i>StandingTall</i> balance exercise programme for fall prevention in people aged 70Âyears and over. Age and Ageing, 2022, 51, .	0.7	3
4	Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review. Pharmacoeconomics, 2021, 39, 63-80.	1.7	6
5	Population-Based Projection of Vision-Related Disability in Australia 2020 – 2060: Prevalence, Causes, Associated Factors and Demand for Orientation and Mobility Services. Ophthalmic Epidemiology, 2021, , 1-10.	0.8	1
6	Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis. Pharmacoeconomics, 2021, 39, 503-519.	1.7	3
7	TEXT4myBACK: A Text Message Intervention to Improve Function in People With Low Back Painâ€"Protocol of a Randomized Controlled Trial. Physical Therapy, 2021, 101, .	1.1	7
8	Protocol of a 12-month multifactorial eHealth programme targeting balance, dual-tasking and mood to prevent falls in older people: the <i>StandingTall</i> + randomised controlled trial. BMJ Open, 2021, 11, e051085.	0.8	4
9	E-health StandingTall balance exercise for fall prevention in older people: results of a two year randomised controlled trial. BMJ, The, 2021, 373, n740.	3.0	48
10	Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS). BMJ Open, 2021, 11, e045929.	0.8	1
11	Implementation of the $\langle i \rangle$ StandingTall $\langle i \rangle$ programme to prevent falls in older people: a process evaluation protocol. BMJ Open, 2021, 11, e048395.	0.8	2
12	Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. Stroke, 2021, 52, 2502-2509.	1.0	10
13	Gender, health and ageing in Fiji: a mixed methods analysis. International Journal for Equity in Health, 2021, 20, 205.	1.5	О
14	Relationship between obesity and school absenteeism in Australian children: Implications for carer productivity. Obesity Research and Clinical Practice, 2021, 15, 587-592.	0.8	6
15	Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-Score. Pharmacoeconomics, 2020, 38, 375-384.	1.7	4
16	Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2020, 19, 651-660.	4.9	90
17	Effectiveness of child restraint legislation to reduce motor vehicle related serious injuries and fatalities: A national interrupted time series analysis. Accident Analysis and Prevention, 2020, 142, 105553.	3.0	5
18	Impact of overweight and obesity on life expectancy, quality-adjusted life years and lifetime costs in the adult population of Ghana. BMJ Global Health, 2020, 5, e003332.	2.0	6

#	Article	IF	Citations
19	A computerâ€guided quality improvement tool for primary health care: costâ€effectiveness analysis based on <scp>TORPEDO</scp> trial data. Medical Journal of Australia, 2020, 213, 73-78.	0.8	7
20	Selfâ€rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCEâ€ON trials. Diabetic Medicine, 2020, 37, 1379-1385.	1.2	9
21	Weight status and health-related quality of life during childhood and adolescence: effects of age and socioeconomic position. International Journal of Obesity, 2020, 44, 637-645.	1.6	27
22	Optimising TRIUMPH with 6·25 mg chlorthalidone – Authors' reply. The Lancet Global Health, 2020, 8, e176.	2.9	0
23	Can Reducing Childhood Obesity Solve the Obesity Crisis in Australia?. Obesity, 2020, 28, 857-859.	1.5	5
24	Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. The Lancet Global Health, 2019, 7, e1359-e1366.	2.9	24
25	Socioeconomic inequalities in obesity: modelling future trends in Australia. BMJ Open, 2019, 9, e026525.	0.8	16
26	Can the Target Set for Reducing Childhood Overweight and Obesity Be Met? A System Dynamics Modelling Study in New South Wales, Australia. Systems Research and Behavioral Science, 2019, 36, 36-52.	0.9	21
27	New Blood Pressure Guidelines Pose Difficult Choices for Australian Physicians. Circulation Research, 2019, 124, 975-977.	2.0	13
28	Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. The Lancet Global Health, 2019, 7, e376-e384.	2.9	27
29	A New Model for Evaluation of Interventions to Prevent Obesity in Early Childhood. Frontiers in Endocrinology, 2019, 10, 132.	1.5	13
30	Costs and effects of interventions targeting frequent presenters to the emergency department: a systematic and narrative review. BMC Emergency Medicine, 2019, 19, 83.	0.7	24
31	Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. International Journal of Obesity, 2019, 43, 782-789.	1.6	48
32	What is the value of a driver licence? A contingent valuation study of Australian adults. Transportation Research, Part A: Policy and Practice, 2018, 108, 25-34.	2.0	5
33	Costâ€effective options for the prevention and management of gastrointestinal and liver disease in the Asia–Pacific region. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 121-127.	1.4	1
34	Fewer orbital fractures treated at St Vincent's Hospital after lockout laws introduced in Sydney. Medical Journal of Australia, 2018, 208, 174-174.	0.8	15
35	Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 2018, 13, e0190688.	1.1	15
36	Medication non-adherence in a cohort of chronically ill Australians: A case of missed opportunities., 2018, 47, 556-562.		4

3

#	Article	IF	CITATIONS
37	Medication non-adherence in a cohort of chronically ill Australians: A case of missed opportunities. Australian Journal of General Practice, 2018, 47, 556-562.	0.3	3
38	Making guidelines for economic evaluations relevant to public health in Australia. Australian and New Zealand Journal of Public Health, 2017, 41, 115-117.	0.8	7
39	Combination Pills for Treatment of High Blood Pressure: Cost-effectiveness in The Asia Pacific Region. Heart Lung and Circulation, 2017, 26, 313-315.	0.2	0
40	Modelling obesity trends in Australia: unravelling the past and predicting the future. International Journal of Obesity, 2017, 41, 178-185.	1.6	77
41	Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort. European Journal of Preventive Cardiology, 2017, 24, 1660-1669.	0.8	34
42	Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis. British Journal of General Practice, 2017, 67, e598-e608.	0.7	16
43	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. International Journal for Equity in Health, 2017, 16, 108.	1.5	7
44	How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus?Âa Systematic Review. Pharmacoeconomics, 2017, 35, 319-329.	1.7	13
45	Comparison of the HUI3 and the EQ-5D-3L in a nursing home setting. PLoS ONE, 2017, 12, e0172796.	1.1	7
46	Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia, 2016, 59, 1167-1176.	2.9	81
47	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment, 2015, 19, 1-402.	1.3	30
48	Economic evaluation of "healthy beginnings―an early childhood intervention to prevent obesity. Obesity, 2014, 22, 1709-1715.	1.5	31
49	Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden. Diabetes Care, 2014, 37, 2974-2981.	4.3	44
50	A Meta-Analysis of the Relative Risk of Mortality for Type 1 Diabetes Patients Compared to the General Population: Exploring Temporal Changes in Relative Mortality. PLoS ONE, 2014, 9, e113635.	1.1	24
51	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment – systematic review and modelling of progression and cost-effectiveness. Health Technology Assessment, 2014, 18, 1-128.	1.3	29
52	Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia, 2013, 56, 973-984.	2.9	132
53	Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes. Pharmacoeconomics, 2013, 31, 509-518.	1.7	10
54	PDB52 Cost-Effectiveness of Renal Screening Strategies and Treatment Options for Patients With Type 1 Diabetes in the United Kingdom. Value in Health, 2012, 15, A180.	0.1	0

THOMAS LUNG

#	Article	IF	CITATION
55	A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Quality of Life Research, 2011, 20, 1669-1678.	1.5	56
56	Change in bias in self-reported body mass index in Australia between 1995 and 2008 and the evaluation of correction equations. Population Health Metrics, 2011, 9, 53.	1.3	38